Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02640209
Recruitment Status : Active, not recruiting
First Posted : December 28, 2015
Last Update Posted : July 3, 2019
Sponsor:
Information provided by (Responsible Party):
University of Pennsylvania

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : October 2019
  Estimated Study Completion Date : December 2019